An Open-Label, Repeated-Dose Assessment of Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
Latest Information Update: 25 Aug 2025
At a glance
- Drugs Zilucoplan (Primary)
- Indications Amyotrophic lateral sclerosis; COVID 2019 infections; Myasthenia gravis
- Focus Pharmacokinetics
- Sponsors UCB Biopharma
Most Recent Events
- 08 Aug 2025 Planned End Date changed from 25 May 2026 to 22 Jul 2026.
- 08 Aug 2025 Planned primary completion date changed from 25 May 2026 to 22 Jul 2026.
- 20 Jul 2025 Last checked against ClinicalTrials.gov record.